Nutlin-3

Catalog No.S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

Size Price Stock Quantity  
In DMSO USD 185 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  •  

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell death dis 2012 3, e294. Nutlin-3 purchased from Selleck.

    Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

  • Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
Targets
Mdm2 [5]
(Cell-free assay)
180 nM
In vitro

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 M3PleWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\URXk2yqEQvF2= MWq0POKhcA>? NYLF[|VX[myxY3vzJFI4NU:KQz3pcoR2[2WmIHPlcIwheHKxbHnm[ZJifGmxbjDjc41x[XKjYnzlJJRwKHSqYYSgc4Yh[mG|YXygcIV3\Wy| MmqwNlY{PTB3NkW=
NP69 MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTNzLk[5xtEzNjV2IN88US=> MkTNNlYzPTJ3N{W=
NP460 M3XZUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLjZnRrUUN3ME2yNk45PcLzMT6xPEDPxE1? NFi3R4wzPjJ3MkW3OS=>
C666-1 NGnJUlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjnTWM2OD1zOT65OeKyQC57MzFOwG0> M33jdFI3OjV{NUe1
C666-1 MWnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFLNRm0yOCEEtV2= NVTSUlJCPDhiaB?= MkPQSG1UVw>? NGr5XHh{\W6|aYTpfoV{KEN4Nk[tNUBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDjbZNxdGG2aX6= MV[yOlI2OjV5NR?=
C666-1  MUfGeY5kfGmxbjDBd5NigQ>? MXOxNEDDvU1? MWOyOEBp NInlRYdFVVOR MofkZYN1cX[jdHXzJJRp\SCyNUOgdIF1cHejeTygeZBz\We3bHH0bY5oKHB3MzygdFIyKGGwZDDN[I0z NHnFUGUzPjJ3MkW3OS=>
C666-1 NELseXNCeG:ydH;zbZMhSXO|YYm= MWexNEDDvU1? M1mwZVQ5Nzd{IHi= MV7EUXNQ MmD2d4Vve2m2aYrld{BEPjZ4LUGgZ4VtdHNidH:gZ4l{eGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz MXGyOlI2OjV5NR?=
A549 NVTE[JlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV2yOEBp NWTrU3ZuUUN3ME2xO{43QCEEsTC0MlUzKM7:TR?= MoTUNlYyOjV{M{C=
A549-NTC Mne5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLNcXl1OjRiaB?= MVHJR|UxRTF7LkSyJOKyKDFwOU[g{txO MV:yOlEzPTJ|MB?=
A549-920 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYSwSmV5OjRiaB?= NX:yXWd2UUN3ME2zN{45PSEEsTC0Mlg1KM7:TR?= NGLGZXczPjF{NUKzNC=>
CRL-5908 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:5cFEzPCCq NFjRZWZKSzVyPUO4MlcyKMLzIEKuOFMh|ryP M4nITlI3OTJ3MkOw
L6 NWj5PIdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFuyengyOMLizszNxsA> M1;Nb|I1NzR6L{eyJIg> M3y5c2ROW09? NXXsbFRTcW6qaXLpeJMh[2WubIOgdJJwdGmoZYLheIlwdiCjbnSg[Iln\mW{ZX70bYF1cW:w M2nmV|I2QDdzN{m0
C2C12 M4\FXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO5dZptOTEEoN88UeKh Ml33NlQwPDhxN{KgbC=> M3n0c2ROW09? M{mzfIlvcGmkaYTzJINmdGy|IIDyc4xq\mW{YYTpc44h[W6mIHTp[oZmemWwdHnheIlwdg>? MnjzNlU5PzF5OUS=
MCF-7  MXjGeY5kfGmxbjDBd5NigQ>? MUixNOKh|ryP Mmq0SG1UVw>? MnrabY5pcWKrdIOgZ5lkdGmwIFSxJIFv\CCGaXPlduKh MUiyOVcxOjdyMx?=
DU4475  NV73SJhTTnWwY4Tpc44hSXO|YYm= NV\TbG1KPS9zMD:yNEDPxE1? NX\TcoJsOjUEoHi= M1r4fYRwf26{ZXf1cIF1\XNiVH;jZU0yKGSxc3Wg[IVx\W6mZX70cJk> M{XBOFI2PTR5MUe0
SMMC-7721 NH:zeJdHfW6ldHnvckBCe3OjeR?= NI\pSXcyOCEQvF2= NGjiVZA1QCCq NXPHcVdqTE2VTx?= M2TXSYNifXOnczDEUmEhTFOEIHThcYFo\Q>? NEnHPIIzPTV2NEO2NS=>
SMMC-7721 MX;GeY5kfGmxbjDBd5NigQ>? NIXHUlIyOCEQvF2= M3W2XVQ5KGh? M1XIUmROW09? NH;QeoxqdmS3Y3XzJJRp\SClaILvcYF1cW5vYn;1coQheHKxdHXpckBKTklzNjD0c{Bx[XK2aXHscJkhdG:lYXzpfoUhcW5idHjlJIN6fG:ybHHzceKh NEH1ZoEzPTV2NEO2NS=>
SMMC-7721 Mk\MSpVv[3Srb36gRZN{[Xl? M3nvW|ExKM7:TR?= NH;iRYo1QCCq MUXEUXNQ M3fUUYlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZtMgTWZPSjIEoH3SUmE> NYnPb3IxOjV3NESzOlE>
SMMC-7721 NEWzVW5HfW6ldHnvckBCe3OjeR?= M4jWVVExKM7:TR?= M3X3ZVM3KGh? MXXEUXNQ NXnRNJJK[2G3c3XzJJRp\SCnY4TvdIlkKGW6cILld5Nqd25ib3[gTWZKOTZ? NFHxbIwzPTV2NEO2NS=>
MCF-7 NFi5RnVHfW6ldHnvckBCe3OjeR?= NUHwfY9YOTEEoN88US=> NXK0SoN[OC1{NDDo NEL3dIdqdmS3Y3XzJJA2OyCjbnSgdFIyN0OrcEG= NIjBNZczPTR6MkO3Ny=>
OVCAR10 M3z1cWZ2dmO2aX;uJGF{e2G7 MVKxNOKh|ryP MV:yNYjDqA>? NX\GT4NGTE2VTx?= MX7pcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz M1fJfVI2PDJ4NUS4
NCI-H23 NG[5e5lHfW6ldHnvckBCe3OjeR?= MY[xNOKh|ryP NELPNIszOWkEoB?= NW\4c|AxTE2VTx?= NVG5WlRQcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? MViyOVQzPjV2OB?=
A2780 MX\GeY5kfGmxbjDBd5NigQ>? NWnVWJJFOTEEoN88US=> NHG0PIIzOWkEoB?= NGrQXIFFVVOR MlfvbY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> NFrIU|QzPTR{NkW0PC=>
NCI-H23 NF35ZppHfW6ldHnvckBCe3OjeR?= MVWxNOKh|ryP NX3Mdm5rOjGqwrC= NHzTVVhFVVOR NHzrb2Fl\WO{ZXHz[ZMhfGinIF\vfG0yKGyndnXsdy=> NX:5PHNvOjV2Mk[1OFg>
A2780 Mo[5SpVv[3Srb36gRZN{[Xl? NVrEbJUyOTEEoN88US=> NGHBV|gzOWkEoB?= M2W0XmROW09? NXHsTYds\GWlcnXhd4V{KHSqZTDGc5hOOSCuZY\lcJM> NH[0[FczPTR{NkW0PC=>
HCT116  NGjUc45HfW6ldHnvckBCe3OjeR?= NWD5VopCOTBiwsXN NGXHcXQzPCCq MkLIZ4F2e2W|IHGgdFU{NWSncHXu[IVvfCC2ZYTyZZBtd2mmIFexMYFzemW|dDDpckBlcXCub3nkJGhEXDFzNjDjcI9v\XNiREOgZY5lKER6 MUCyOVM5ODB3NR?=
MCF-10CA1a NV\1RZBWTnWwY4Tpc44hSXO|YYm= NWjBTFduOTEEoN88US=> NYTtT2tCPDhiaB?= NHrBe29FVVOR M1v3dolvcGmkaYTzJIJie2GuIHnueoF{cW:wIHHu[EBz\WS3Y3XkJHRITi4QskOtbY5lfWOnZDDpcpZie2mxbjD0c{Bj[XOjbDDs[ZZmdHN? M{\nUFI2OjV5N{K5
MCF-10A1  NGjYTVZHfW6ldHnvckBCe3OjeR?= MUWxNOKh|ryP NYOwS25FOjRxNEigbC=> NF3YTYpFVVOR NITmSHFqdmirYnn0d{BucWe{YYTpc44hd2Zibn;ycYFtKGK{ZXHzeEBmeGm2aHXsbYFtyqB? NU\3VldXOjV{NUe3Nlk>
MCF-10CA1a MlLMSpVv[3Srb36gRZN{[Xl? NUfKToU2OTEEoN88US=> NUPJTmFPOjRiaB?= MXvEUXNQ NH;rXGxl\WO{ZXHz[ZMhfGinIGTHSk3PujNvaX7keYNm\CCvUl7BJIxmfmWuczDv[m1OWDJuwrDNUXA6NCCjbnVCpIlvfGWpcnnuxsDPusLiMx?= NVXm[Xd3OjV{NUe3Nlk>
MCF-10CA1a NILa[GpHfW6ldHnvckBCe3OjeR?= NUj0cFNzOTEEoN88US=> NUPScHRpOjRiaB?= NXLNTlZvTE2VTx?= M2Ta[4lvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= MWmyOVI2Pzd{OR?=
SK-BR-7 MVnGeY5kfGmxbjDBd5NigQ>? M4jqcVExyqEQvF2= M3vIUFI1KGh? MUPEUXNQ M1XaN4lvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= NFHmfpczPTJ3N{eyPS=>
SUM102PT MkjoSpVv[3Srb36gRZN{[Xl? MUexNOKh|ryP NG\uWXUzPCCq NFzQdGlFVVOR M1HLSYlvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= NFSyPG8zPTJ3N{eyPS=>
RAW 264.7 M4HtZWZ2dmO2aX;uJGF{e2G7 NUT3WoduOTEEoN88US=> NVnHPVdzOzBibXnu MlXqdJJmfmWwdIOgeIhmKHB3MzDy[YR2[3Srb36gbY4hemW|cH;ud4UhfG9iTGDT Moj6NlUyPzJ3NEe=
RAW 264.7 MoXSSpVv[3Srb36gRZN{[Xl? NIHYdI4yOMLizszN NUXzNXY5OzBibXnu M2fRbJJm\HWlZYOgeIhmKEySUz3heYdu\W62ZXSgeIhmKE6ILd86RkBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZYN1cX[rdIm= MoXkNlUyPzJ3NEe=
RAW 264.7 M4P5c2Z2dmO2aX;uJGF{e2G7 NGOzU2QyOMLizszN NGjSOWY{OCCvaX6= MkixbY5pcWKrdIOgUHBUNWmwZIXj[YQhVk9icILv[JVkfGmxbtMg M{\SeFI2OTd{NUS3
MCF7  M3fxPWNmdGxiVnnhZoltcXS7IFHzd4F6 M{PYTlIvPSEEtV2= NH72PJY2KGR? NYnaRnhkTE2VTx?= MVfz[Y5{cXSrenXzJG1ETjdidH:gVGFTWCCrbnjpZol1cW:w MlzYNlUxQDV7MEK=
MCF7  M4W2UmZ2dmO2aX;uJGF{e2G7 MVOyMlUhyrWP MYK0PEBp NFXOSHVFVVOR NGXj[|Rl\WO{ZXHz[ZMhfGinIHjvcY9td2exdYOgSHNDKHKncHHpdkBnemWzdXXuZ4lmew>? M2fXV|I2ODh3OUCy
ACHN M3z6OmNmdGxiVnnhZoltcXS7IFHzd4F6 NULWXY5EOC53LUGwJO69VQ>? NE\pT2QxNTZiZB?= NFO1SYhFVVOR NHHtfXBqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NIXVeYszPTB4N{e4Oy=>
Caki-2 MXzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXjSR3QzOC53LUGwJO69VQ>? NH3MfHQxNTZiZB?= NIDyZWpFVVOR Ml[xbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MkXnNlUxPjd5OEe=
A498 MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M17vdVAvPS1zMDFOwG0> MVOwMVYh\A>? NV:1ZZBNTE2VTx?= M3LN[4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXfNN404OjVyNke3PFc>
115 MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MUSwMlUuOTBizszN MXWwMVYh\A>? NXzrOoxjTE2VTx?= NX;EXY1OcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFTHR3QzPTB4N{e4Oy=>
117 Ml3oR4VtdCCYaXHibYxqfHliQYPzZZk> MkS1NE42NTFyIN88US=> NUjBWpdJOC14IHS= MoftSG1UVw>? MVjpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmHoNlUxPjd5OEe=
ACHN MVjGeY5kfGmxbjDBd5NigQ>? NHjBdXcxNjVxMT:1JO69VQ>? NI\4XXE1QCCq MWLEUXNQ NIqyWW5t\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= NFeybY8zPTB4N{e4Oy=>
Caki-2 NWfEcW0xTnWwY4Tpc44hSXO|YYm= NEHtfnQxNjVxMT:1JO69VQ>? M4fyXlQ5KGh? M{m5e2ROW09? MnTtcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? M32zSVI2ODZ5N{i3
A498 M{nMZ2Z2dmO2aX;uJGF{e2G7 MkHvNE42NzFxNTFOwG0> MVG0PEBp NWizdYpRTE2VTx?= Mn3JcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? M4r2cFI2ODZ5N{i3
115 NUjZfZQ5TnWwY4Tpc44hSXO|YYm= MVOwMlUwOS93IN88US=> M2TWflQ5KGh? NXvWUnVsTE2VTx?= MoGwcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? NX\3TGZLOjVyNke3PFc>
ACHN M3XGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjN[5EyPSEQvF2= NVLWelc2PDhiaB?= NXzZXJdHTE2VTx?= MlTTbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg M3rTcFI2ODZ5N{i3
Caki-2 M{fLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXZZ4puPSEQvF2= NVHVS|VzPDhiaB?= NEfUfoVFVVOR M3vHTIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> MnziNlUxPjd5OEe=
A498 NWLFW3dwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HlfVUh|ryP M1HaUlQ5KGh? NULyfYRYTE2VTx?= MWfpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= NX3tOGVtOjVyNke3PFc>
115 NHWyNmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvzO3k2KM7:TR?= M1rxR|Q5KGh? MkTYSG1UVw>? MVnpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= NF;2bGozPTB4N{e4Oy=>
ACHN NVPFVI1MTnWwY4Tpc44hSXO|YYm= MY[1JO69VQ>? MV:0PEBp M4jZXGROW09? M3TVT4lv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= NFvwW3gzPTB4N{e4Oy=>
Caki-2 MVfGeY5kfGmxbjDBd5NigQ>? NUDCZ21wPSEQvF2= NX\MUnVIPDhiaB?= M3TVNmROW09? M2TBOYlv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= NVHPcZNmOjVyNke3PFc>
A498 MVrGeY5kfGmxbjDBd5NigQ>? M3jRV|Uh|ryP Mo\TOFghcA>? NX\nW2xJTE2VTx?= MlfxbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= Mmf5NlUxPjd5OEe=
115 NI\yUWxHfW6ldHnvckBCe3OjeR?= Ml\jOUDPxE1? MmHsOFghcA>? MofBSG1UVw>? M4XUXYlv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= Mn\mNlUxPjd5OEe=
MOLM-13 NFXSSXBHfW6ldHnvckBCe3OjeR?= MnS2OuKh|ryP NGPNTZExNThiaB?= NYPNOmJLTE2VTx?= MlXHbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZicEWzMEBOTE1{LDDwNlEh[W6mIHHj[ZR6dGG2ZXSgdFU{ MWiyOFg5PTB6Mh?=
MOLM-13 Ml2ySpVv[3Srb36gRZN{[Xl? NFTUOGo3yqEQvF2= MoHHOkBp M13jcGROW09? NVzWPIZ4\W6qYX7j[ZMhfGinIHHj[ZR6dGG2aX;uJI9nKGirc4TvcoUhUDKEIHHu[EBp\WG2IIPoc4NsKHC{b4TlbY5{KEi|cEK3JIFv\CCKc4C5NC=> NHXQU44zPDh6NUC4Ni=>
HepG2 NFfwcY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn4O|IhcA>? NIqyVGVFVVOR MYDJR|UxRTN3Lki2JOKyKDJwOTFOwG0> NEHDfWwzPDh6NEiwPS=>
HepG2/As NXXIUGI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWq3NkBp NX\U[ItXTE2VTx?= MkCwTWM2OD14OD6xN{DDuSB7Lk[g{txO MUmyOFg5PDhyOR?=
SMMC7721 NYnKbZl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYG3NkBp MWrEUXNQ MnnaTWM2OD1|MT6yPEDDuSB2LkKg{txO NFjxPIszPDh6NEiwPS=>
SMMC7721/Ac MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHJR3pKPzJiaB?= MWHEUXNQ NGfWN5dKSzVyPUW1MlIyKMLzIEWuNFMh|ryP M3v0e|I1QDh2OEC5
Huh-7 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7YOmc4OiCq MkjGSG1UVw>? M4XFZ2lEPTB;M{OuPVYhyrFiMz65JO69VQ>? M{TQcFI1QDh2OEC5
Hep3B MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3TO|IhcA>? NUfibZAyTE2VTx?= NVXB[XhIUUN3ME2yNE4yQCEEsTCxMlg1KM7:TR?= MV[yOFg5PDhyOR?=
HepG2 Mmf2RZBweHSxc3nzJGF{e2G7 MlfzbY5lfWOnczDhdI9xfG:|aYO= M1PIV|I1QDh2OEC5
SMMC7721 MkDkRZBweHSxc3nzJGF{e2G7 M{W2UIlv\HWlZYOgZZBweHSxc3nz MY[yOFg5PDhyOR?=
Huh-7 NV\IcFdISXCxcITvd4l{KEG|c3H5 NF\kWXFqdmS3Y3XzJIFxd3C2b4Ppdy=> NEXFXpkzPDh6NEiwPS=>
Hep3B MUTBdI9xfG:|aYOgRZN{[Xl? MmXKbY5lfWOnczDhdI9xfG:|aYO= MX[yOFg5PDhyOR?=
U2OS  NECwV3dHfW6ldHnvckBCe3OjeR?= MYmyNEDPxE1? MYeyOEBp MV3pcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBDS0x{QUGsJGJEVFiOwrDhcoRDS0yZ NGjUR|QzPDh4N{K1PS=>
AML2 M3n2b2Fxd3C2b4Ppd{BCe3OjeR?= NULQU4VkOi9zMDFOwG0> MVmyOE81QCCq MUXpcoR2[2W|IHHwc5B1d3Orcx?= MnGwNlQ3PTl5NEm=
MOML13 M{K2[2Fxd3C2b4Ppd{BCe3OjeR?= NUDzfJVFOi9zMDFOwG0> MYWyOE81QCCq NVPiPHZScW6mdXPld{BieG:ydH;zbZM> NELlTXYzPDZ3OUe0PS=>
AML2 NVv5XFNsTnWwY4Tpc44hSXO|YYm= MljhNVDPxE1? NXP2dlBZOi92IHi= MULpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= NVXhemFTOjR4NUm3OFk>
AML3 MoTVSpVv[3Srb36gRZN{[Xl? NHjiRokyOM7:TR?= M{G0SlIwPCCq MV3pcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= MkPGNlQ3PTl5NEm=
MOML13 Mly2SpVv[3Srb36gRZN{[Xl? M{ezclEx|ryP NGS5UngzNzRiaB?= NEflbVJqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> MnW0NlQ3PTl5NEm=
BeWo M1fuemZ2dmO2aX;uJGF{e2G7 M1\uU|MxKML3TR?= MonwNlQhcA>? Mo\ubY5kemWjc3XzJJA2OyxiTXTtNkwheDJzIHHu[EBRfW2jIHH0JJRp\SCycn;0[YlvKGyndnXs M3\5U|I1PDl6MUW0
BeWo NH35b|lCeG:ydH;zbZMhSXO|YYm= MUmzNEDDvU1? NX\tTYtDOjRiaB?= NWTGRXpRcW6lcnXhd4V{KGGyb4D0c5Nqew>? NHrkdVEzPDR7OEG1OC=>
OCI MWrGeY5kfGmxbjDBd5NigQ>? MVuxNEDPxE1? NGf2RmYzPCCq NFTPeZV2eHKnZ4XsZZRmeyC2aHWgV29EWy1zIHX4dJJme3Orb36= NWrMeFl3OjR2N{O1OlI>
MOLM NVntbJJvTnWwY4Tpc44hSXO|YYm= MkO1NVAh|ryP NF3PZ|QzPCCq M3jiU5VxemWpdXzheIV{KHSqZTDTU2NUNTFiZYjwdoV{e2mxbh?= M2rR[FI1PDd|NU[y
U2OS  NXj1UG1CTnWwY4Tpc44hSXO|YYm= MlTCNlAh|ryP M1L6PVI1KGh? NHj5SGtqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUhUE9vMTDwdo91\WmwIHHzJJdmdGxiYYOgeIhmKHB3MzDwdo91\Wmw M4XDV|I1OzZ4MEC3
RKO MXfGeY5kfGmxbjDBd5NigQ>? NXvxfW04OjBizszN M1fOU|I1KGh? NXPFbINkcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKEiRLUGgdJJwfGWrbjDhd{B4\WyuIHHzJJRp\SCyNUOgdJJwfGWrbh?= MYeyOFM3PjByNx?=
U2OS  MkK4SpVv[3Srb36gRZN{[Xl? M2TES|IxKM7:TR?= M2f5PVI1KGh? MUfpcoR2[2W|IFjPMVEh\XiycnXzd4lwdiCjdDD0bIUhdGW4ZXygc4YhfHKjboPjdolxfGmxbh?= MnvWNlQ{PjZyMEe=
RKO NYTGVIl7TnWwY4Tpc44hSXO|YYm= NW\M[YxyOjBizszN MWmyOEBp NUK5TW9YcW6mdXPld{BJVy1zIHX4dJJme3Orb36gZZQhfGinIHzleoVtKG:oIITyZY5{[3KrcITpc44> NHe4SpMzPDN4NkCwOy=>
SMMC-7721  M3XWVGNmdGxiVnnhZoltcXS7IFHzd4F6 Mlr0NU4zPS1{MDFOwG0> M3LXS|I1NzR6L{eyJIg> NULCU2dDTE2VTx?= M{DNe4lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 MknVNlQzQDZ|MUK=
HuH-7 MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NET4S|YyNjJ3LUKwJO69VQ>? NYrjWZpvOjRxNEivO|IhcA>? MWPEUXNQ MmjnbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= MnGzNlQzQDZ|MUK=
SMMC-7721  M3n1eGFxd3C2b4Ppd{BCe3OjeR?= MlzaNlAh|ryP NXL4Rm1KPDhiaB?= NXvDcYs1TE2VTx?= NHL5ZYJqdmS3Y3XzJIFxd3C2b4Ppdy=> M1PaVlI1Ojh4M{Gy
HuH-7 NUXNcZZ4SXCxcITvd4l{KEG|c3H5 MWWyNEDPxE1? NV7WS2Z6PDhiaB?= M2nTeGROW09? MWPpcoR2[2W|IHHwc5B1d3Orcx?= M{jtc|I1Ojh4M{Gy
SMMC-7721  MkHBSpVv[3Srb36gRZN{[Xl? Mmm4NVAh|ryP NIfqd|Y{PiCq MonDSG1UVw>? NWTmSZBD\G:5bj3y[Yd2dGG2ZYOgeIhmKHC{b4TlbY4h\XiycnXzd4lwdiCuZY\lcEBw\iCyaH;zdIhwNVOnckO5Nk1xPTN? M4fQblI1Ojh4M{Gy
HuH-7 MV7GeY5kfGmxbjDBd5NigQ>? M2r2UVExKM7:TR?= NIPlfoM{PiCq M1:5TmROW09? Mmrs[I94di2{ZXf1cIF1\XNidHjlJJBzd3SnaX6g[ZhxemW|c3nvckBt\X[nbDDv[kBxcG:|cHjvMXNmejN7Mj3wOVM> M1W4[lI1Ojh4M{Gy
AT2 NEfa[YtHfW6ldHnvckBCe3OjeR?= M3jKSFUwOTBizszN M3rmeoxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li NUf4TnlrOjR{NECyNFM>
REH MVPGeY5kfGmxbjDBd5NigQ>? NY[4W4JpPS9zMDFOwG0> NIS1Z|dt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= NHnUZ4czPDJ2MEKwNy=>
UoCB6 NGHoOHBHfW6ldHnvckBCe3OjeR?= M3vmflUwOTBizszN NWr0bXBxdGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= M4HCWlI1OjRyMkCz
AT2 NVyxdHh7S2WubDDWbYFjcWyrdImgRZN{[Xl? NUTvOmJXOC1{NTFOwG0> M4XpV4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NIjwWI0zPDJ2MEKwNy=>
REH NYXoe5plS2WubDDWbYFjcWyrdImgRZN{[Xl? MWWwMVI2KM7:TR?= Mne5bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M3TLdlI1OjRyMkCz
UoCB6 NIPYeolE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVnlO3puOC1{NTFOwG0> MUTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MY[yOFI1ODJyMx?=
A2780 Mnr6SpVv[3Srb36gRZN{[Xl? MoiwOU8yOC9{MDFOwG0> MWWyOEBp Mk\TeZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? MWmyOFE{PjF2Nx?=
H460 M1zkRWZ2dmO2aX;uJGF{e2G7 M3HuVVUwOTBxMkCg{txO M1\CRlI1KGh? M1rubJVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi NGPMPZkzPDF|NkG0Oy=>
Lovo  NVL1R5FITnWwY4Tpc44hSXO|YYm= NUXoRWpOPS9zMD:yNEDPxE1? NFPtdY4zPCCq M3zoVZVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi MYWyOFE{PjF2Nx?=
A2780 NGPMdlBCeG:ydH;zbZMhSXO|YYm= MVy1M|ExNzJyIN88US=> MV2yOEBp M{HLXoVvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN NF7V[IgzPDF|NkG0Oy=>
H460 MkPGRZBweHSxc3nzJGF{e2G7 M2nrfVUwOTBxMkCg{txO MVOyOEBp MUjlcohidmOnczDhdI9xfG:|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=> Mlr2NlQyOzZzNEe=
Lovo  MorKRZBweHSxc3nzJGF{e2G7 MUC1M|ExNzJyIN88US=> NV\QWHRxOjRiaB?= NYrIXFZE\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? MV[yOFE{PjF2Nx?=

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
Cell Research:

[1]

+ Expand
  • Cell lines: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • Concentrations: Dissolved in DMSO, final concentrations ~ 30 μM
  • Incubation Time: 8, 24, and 48 hours
  • Method:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • Formulation: Formulated in 2% Klucel, 0.5% Tween 80
  • Dosages: 200 mg/kg
  • Administration: Orally, twice a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water <1 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.5
Formula

C30H30Cl2N4O4

CAS No. 890090-75-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3 | Nutlin-3 supplier | purchase Nutlin-3 | Nutlin-3 cost | Nutlin-3 manufacturer | order Nutlin-3 | Nutlin-3 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID